[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368633-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368633-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","state-of-the-art-in-car-based-therapy-in-vivo-car-production-as-a-revolution-in-cell-based-cancer-treatment","State of the art in CAR-based therapy - In vivo CAR production as a revolution in cell-based cancer treatment","","Chimeric antigen receptor (CAR) therapy has achieved meaningful responses in relapsed or refractory hematological cancers by directly targeting tumor cells. Despite clinical promise, major obstacles persist, especially in drug production, resistance in solid tumors, and treatment-related side effects. Missed cases can result from manufacturing issues, prolonged production timelines, and high costs. This review contrasts traditional in vitro manufacturing with in vivo gene delivery, highlighting how faster in-body CAR gene introduction may reduce preparation failures, lower overall burden, and support clinical translation through proposed solutions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/state-of-the-art-in-car-based-therapy-in-vivo-car-production-as-a-revolution-in-cell-based-cancer-treatment/368633/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/state-of-the-art-in-car-based-therapy-in-vivo-car-production-as-a-revolution-in-cell-based-cancer-treatment/368633.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main challenges of CAR-based therapy highlighted in the review?","Question",{"text":63,"@type":64},"The review emphasizes production-related hurdles, resistance in solid tumors, and side effects. Manufacturing issues, prolonged production times, and high costs can also lead to missed patients during drug preparation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does in vivo CAR production differ from the traditional in vitro manufacturing process?",{"text":68,"@type":64},"In the traditional approach, immune cells are collected, modified in the laboratory to express the CAR gene, and then reinfused into the patient. In the in vivo approach, the CAR gene is introduced to immune cells inside the body to enable earlier treatment initiation.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review aim to cover regarding in vivo CAR therapy?",{"text":72,"@type":64},"The review elaborates on the production and treatment process for in vivo CAR, evaluates benefits and challenges, and presents available solutions for incorporating this approach into clinical practice.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368633,1790647787,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Cellular Oncology (2025) 48:859–883  \n[https://doi.org/10.1007/s13402-025-01056-7](https://doi.org/10.1007/s13402-025-01056-7)  \nREVIEW  \nState ofthe art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment  \nAbdolreza Esmaeilzadeh1,2 · Kaveh Hadiloo1,3,4 · SaraYaghoubi4,5 · Masoud Hassanzadeh Makoui6 · Parsa Mostanadi4,5  \nReceived: 24 January 2025 / Accepted: 19 March 2025 / Published online: 22 April 2025 © The Author(s) 2025  \nAbstract  \nChimeric antigen receptor (CAR) therapy has successfully treated relapsed/refractory hematological cancers. This strategy can effectively target tumor cells. However, despite positive outcomes in clinical applications, challenges remain to overcome. These hurdles pertain to the production of the drugs, solid tumor resistance, and side effects related to the treatment. Some cases have been missed during the drug preparation due to manufacturing issues, prolonged production times, and high costs. These challenges mainly arise from the in vitro manufacturing process, so reevaluating this process could minimize the number of missed patients. The immune cells are traditionally collected and sent to the laboratory; after several steps, the cells are modified to express the CAR gene before being injected back into the patient’s body. During the in vivo method, the CAR gene is introduced to the immune cells inside the body. This allows for treatment to begin sooner, avoiding potential failures in drug preparation and the associated high costs. In this review, we will elaborate on the production and treatment process using in vivo CAR, examine the benefits and challenges of this approach, and ultimately present the available solutions for incorporating this treatment into clinical practice.  \nKeywords Adoptive cellular immunotherapies · Chimeric antigen receptor · In vivo gene delivery · Antineoplastic protocols · Clinical setting  \nAbbreviations  \nCAR  \nTME  \nNK  \nNKT  \nPBMC  \nChimeric antigen receptor Tumor microenvironment Natural killer  \nNatural killer T  \nPeripheral blood mononuclear celli  \n􀀍 Abdolreza Esmaeilzadeh[a46reza@zums.ac.ir](a46reza@zums.ac.ir)  \nKaveh Hadiloo  \n[kaveh.hadiloo@gmail.com](kaveh.hadiloo@gmail.com)  \nSara Yaghoubi  \n[springmood.sara@gmail.com](springmood.sara@gmail.com)  \nMasoud Hassanzadeh Makoui  \n[dr.m.makoui@zums.ac.ir](dr.m.makoui@zums.ac.ir)  \nParsa Mostanadi  \n[parsamostanadi77@gmail.com](parsamostanadi77@gmail.com)  \n1 Pficell R&D Canadian Institution & Corporation, Profound Future Focused Innovative Cell and Gene Therapy, Pficell Canadian Institution and Corporation, Ontario, Canada  \nPCS hPSC TRUCK  \nGMP  \nYESCARTA  \nInduced pluripotent stem cell  \nhuman pluripotent stem cell  \nT cells redirected for universal cytokines killing  \nGood manufacturing process  \nCAR T cell therapy for certain types of  \n2 Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran  \n3 Department of Surgery, Velayat Clinical Research Development Unit, Qazvin University of Medical Sciences, Qazvin, Iran  \n4 Department of Immunology, Student Research Committee, School of Medicine, Zanjan, Iran  \n5 School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran  \n6 Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran  \nICU  \nBCMA  \nBT  \nCRSGVHD  \nMAS  \nHLH  \nTCRICANS  \nAAV  \nDMD  \nNSAA  \nSMA  \nTTR  \nLNP  \nCRISPR/cas9  \nTAM  \nCHP DC  \nFAP  \nLV VSVssDNA DARPins  \nVLPs DNA  \nRMANOVA  \nsaRNA  \nRNP  \nCARPA  \nIL-6 shRNA pDNAZNFTALEN  \nDSB  \ntDC-Exo  \nEGFR TGF  \nGM-CSF  \nFAP  \nPDX  \nnon-Hodgkin lymphoma Intensive care unit B cell maturation antigen Bridge therapy  \nCytokine release syndrome Graft-versus-host disease  \nMacrophage activation syndrome Hemophagocytic lymphohistiocytosis T cell receptor  \nImmune effector cell-associated neurotoxicity syndrome  \nAdeno-associated virus  \nDuchenne muscular dystrophy The North Star Ambulatory Assessment Spinal muscular atr","cbCaildEk2LJeQWI","https://ap.wps.com/l/cbCaildEk2LJeQWI","pdf",2550181,25,"English","# Abstract\n## Introduction\n# Background\n## Keywords","[{\"question\":\"What are the main challenges of CAR-based therapy highlighted in the review?\",\"answer\":\"The review emphasizes production-related hurdles, resistance in solid tumors, and side effects. Manufacturing issues, prolonged production times, and high costs can also lead to missed patients during drug preparation.\"},{\"question\":\"How does in vivo CAR production differ from the traditional in vitro manufacturing process?\",\"answer\":\"In the traditional approach, immune cells are collected, modified in the laboratory to express the CAR gene, and then reinfused into the patient. In the in vivo approach, the CAR gene is introduced to immune cells inside the body to enable earlier treatment initiation.\"},{\"question\":\"What does the review aim to cover regarding in vivo CAR therapy?\",\"answer\":\"The review elaborates on the production and treatment process for in vivo CAR, evaluates benefits and challenges, and presents available solutions for incorporating this approach into clinical practice.\"}]","State of the art in CAR-based therapy - In vivo CAR production as a revolution in cell-based cancer treatment | PDF",1790177794,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/157120786533d93d274cc0a35be73fcb.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0740a1e8b085960f5622083112a83175.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fe13e5e9ec3cd699d0f117aae8d25a2.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/983d235253ffae1b515bfad444517e33.webp",980,1301]